LEXINGTON, Mass., Sept. 6,
2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib, an
orally available small molecule IRAK4 inhibitor for the treatment
of hematologic malignancies, today announced that James Dentzer, President and Chief Executive
Officer of Curis, will participate at the following
conferences:
The H.C. Wainwright 25th Annual Global Investment
Conference being held September 11 –
13, 2023. Presentation details are as follows:
- Format: Company Presentation
- Date: Tuesday, September 12,
2023
- Time: 8:30am ET
The 2023 Cantor Global Healthcare Conference being held
September 26 – 28, 2023. Presentation
details are as follows:
- Format: Panel Presentation
- Date: Wednesday, September 27,
2023
- Time: 9:10am ET
Webcasts will be available on the Curis website
at www.curis.com in the 'Investors' section.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor
for the treatment of hematologic malignancies. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is
currently undergoing testing in the Phase 1/2 TakeAim Lymphoma
study in patients with hematologic malignancies, such as
non-Hodgkin's lymphoma and other B cell malignancies, both as a
monotherapy and in combination with BTK inhibitor ibrutinib, and
the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid
leukemia and myelodysplastic syndrome, for which it has received
Orphan Drug Designation from the U.S. Food and Drug Administration.
In addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody. Curis is
also party to a collaboration with Genentech, a member of the Roche
Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma. For
more information, visit Curis's website at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-301919160.html
SOURCE Curis, Inc.